Jerusalem, 15 April, 2026 (TPS-IL) — Galmed Pharmaceuticals Ltd., an Israeli clinical-stage biopharmaceutical company, announced research collaboration with Ramot, the technology transfer arm of Tel Aviv University, to evaluate its SCD1 inhibitor Aramchol as a potential targeted therapy for metastatic brain cancer.
The partnership will combine Galmed’s drug development program with findings from Tel Aviv University researchers who identified a link between p53 inactivation and SCD1-driven tumor growth in the brain. The study will use advanced preclinical models developed at TAU to assess whether Aramchol can disrupt the metabolic adaptations that allow cancer cells to spread and survive in the brain.